MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review)

  • Li X
  • Du L
  • Liu Q
  • et al.
N/ACitations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Cachexia denotes a complex metabolic syndrome featuring severe loss of weight, fatigue and anorexia. In total, 50-80% of patients suffering from advanced cancer are diagnosed with cancer cachexia, which contributes to 40% of cancer-associated mortalities. MicroRNAs (miRNAs) are non-coding RNAs capable of regulating gene expression. Dysregulated miRNA expression has been observed in muscle tissue, adipose tissue and blood samples from patients with cancer cachexia compared with that of samples from patients with cancer without cachexia or healthy controls. In addition, miRNAs promote and maintain the malignant state of systemic inflammation, while inflammation contributes to cancer cachexia. The present review discusses the role of miRNAs in the progression of cancer cachexia, and assess their diagnostic value and potential therapeutic value.

Cite

CITATION STYLE

APA

Li, X., Du, L., Liu, Q., & Lu, Z. (2022). MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review). Experimental and Therapeutic Medicine, 24(1). https://doi.org/10.3892/etm.2022.11373

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free